Follow the people · Insider
Mittie Doyle
Mittie Doyle files insider transactions with the SEC as a chief medical officer of Avalo Therapeutics (AVTX). We hold 13 disclosed purchases and sales filed since 1 April 2022, 6 of them in the last 90 days.
- Files forAVTX
- Disclosed buys and sells13 in all, 6 in the last 90 days
- Last disclosure1 September 2026
Positions held
3 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 15 July 2024 — 28 August 2026Chief Medical Officer · Avalo Therapeutics (AVTX)63 Form 4 lines · source: SEC Form 4
- Filed 7 August 2025 — 16 June 2026Director · Cullinan Therapeutics (CGEM)2 Form 4 lines · source: SEC Form 4
- Filed 31 March 2022 — 9 August 2023Director · DICE Therapeutics (DICE)2 Form 4 lines · source: SEC Form 4
Everything they disclosed
67 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 679 shares of Avalo TherapeuticsSEC Form 41 September 2026Common Stock · traded 28 August 2026 · filed 1 September 2026
- ▼ sold on the open market 679 shares of Avalo TherapeuticsSEC Form 41 September 2026Common Stock · traded 28 August 2026 · filed 1 September 2026
- exercised options over 679 shares of Avalo Therapeutics (a derivative holding)SEC Form 41 September 2026Stock Option (Right to Buy) · traded 28 August 2026 · filed 1 September 2026
- exercised options over 1,000 shares of Avalo TherapeuticsSEC Form 419 August 2026Common Stock · traded 17 August 2026 · filed 19 August 2026
- ▼ sold on the open market 1,000 shares of Avalo TherapeuticsSEC Form 419 August 2026Common Stock · traded 17 August 2026 · filed 19 August 2026
- exercised options over 1,000 shares of Avalo Therapeutics (a derivative holding)SEC Form 419 August 2026Stock Option (Right to Buy) · traded 17 August 2026 · filed 19 August 2026
- exercised options over 679 shares of Avalo TherapeuticsSEC Form 412 August 2026Common Stock · traded 10 August 2026 · filed 12 August 2026
- ▼ sold on the open market 679 shares of Avalo TherapeuticsSEC Form 412 August 2026Common Stock · traded 10 August 2026 · filed 12 August 2026
- exercised options over 679 shares of Avalo Therapeutics (a derivative holding)SEC Form 412 August 2026Stock Option (Right to Buy) · traded 10 August 2026 · filed 12 August 2026
- exercised options over 1,000 shares of Avalo TherapeuticsSEC Form 429 July 2026Common Stock · traded 27 July 2026 · filed 29 July 2026
- ▼ sold on the open market 1,000 shares of Avalo TherapeuticsSEC Form 429 July 2026Common Stock · traded 27 July 2026 · filed 29 July 2026
- exercised options over 1,000 shares of Avalo Therapeutics (a derivative holding)SEC Form 429 July 2026Stock Option (Right to Buy) · traded 27 July 2026 · filed 29 July 2026
- exercised options over 2,875 shares of Avalo TherapeuticsSEC Form 42 July 2026Common Stock · traded 30 June 2026 · filed 2 July 2026
- exercised options over 1,779 shares of Avalo TherapeuticsSEC Form 42 July 2026Common Stock · traded 30 June 2026 · filed 2 July 2026
- ▼ sold on the open market 4,654 shares of Avalo TherapeuticsSEC Form 42 July 2026Common Stock · traded 30 June 2026 · filed 2 July 2026
- exercised options over 2,875 shares of Avalo Therapeutics (a derivative holding)SEC Form 42 July 2026Stock Option (Right to Buy) · traded 30 June 2026 · filed 2 July 2026
- exercised options over 1,779 shares of Avalo Therapeutics (a derivative holding)SEC Form 42 July 2026Stock Option (Right to Buy) · traded 30 June 2026 · filed 2 July 2026
- exercised options over 1,450 shares of Avalo TherapeuticsSEC Form 425 June 2026Common Stock · traded 23 June 2026 · filed 25 June 2026
- ▼ sold on the open market 1,450 shares of Avalo TherapeuticsSEC Form 425 June 2026Common Stock · traded 23 June 2026 · filed 25 June 2026
- exercised options over 1,450 shares of Avalo Therapeutics (a derivative holding)SEC Form 425 June 2026Stock Option (Right to Buy) · traded 23 June 2026 · filed 25 June 2026
- was granted 21,781 shares of Cullinan Therapeutics (a derivative holding)SEC Form 418 June 2026Stock Option (Right to Buy) · traded 16 June 2026 · filed 18 June 2026
- had shares withheld for tax on 1,084 shares of Avalo TherapeuticsSEC Form 412 June 2026Common Stock · traded 10 June 2026 · filed 12 June 2026
- exercised options over 679 shares of Avalo TherapeuticsSEC Form 41 June 2026Common Stock · traded 28 May 2026 · filed 1 June 2026
- ▼ sold on the open market 679 shares of Avalo TherapeuticsSEC Form 41 June 2026Common Stock · traded 28 May 2026 · filed 1 June 2026
- exercised options over 679 shares of Avalo Therapeutics (a derivative holding)SEC Form 41 June 2026Stock Option (Right to Buy) · traded 28 May 2026 · filed 1 June 2026
- was granted 43,500 shares of Avalo TherapeuticsSEC Form 426 May 2026Common Stock · traded 21 May 2026 · filed 26 May 2026
- exercised options over 3,000 shares of Avalo TherapeuticsSEC Form 419 May 2026Common Stock · traded 15 May 2026 · filed 19 May 2026
- ▼ sold on the open market 3,000 shares of Avalo TherapeuticsSEC Form 419 May 2026Common Stock · traded 15 May 2026 · filed 19 May 2026
- exercised options over 3,000 shares of Avalo Therapeutics (a derivative holding)SEC Form 419 May 2026Stock Option (Right to Buy) · traded 15 May 2026 · filed 19 May 2026
- exercised options over 1,000 shares of Avalo TherapeuticsSEC Form 47 May 2026Common Stock · traded 5 May 2026 · filed 7 May 2026
- ▼ sold on the open market 10,058 shares of Avalo TherapeuticsSEC Form 47 May 2026Common Stock · traded 6 May 2026 · filed 7 May 2026
- exercised options over 1,000 shares of Avalo Therapeutics (a derivative holding)SEC Form 47 May 2026Stock Option (Right to Buy) · traded 5 May 2026 · filed 7 May 2026
- exercised options over 679 shares of Avalo Therapeutics (a derivative holding)SEC Form 47 May 2026Stock Option (Right to Buy) · traded 5 May 2026 · filed 7 May 2026
- exercised options over 77,905 shares of Avalo Therapeutics (a derivative holding)SEC Form 47 May 2026Stock Option (Right to Buy) · traded 6 May 2026 · filed 7 May 2026
- exercised options over 28,650 shares of Avalo Therapeutics (a derivative holding)SEC Form 47 May 2026Stock Option (Right to Buy) · traded 6 May 2026 · filed 7 May 2026
- exercised options over 679 shares of Avalo TherapeuticsSEC Form 47 May 2026Common Stock · traded 5 May 2026 · filed 7 May 2026
- ▼ sold on the open market 1,679 shares of Avalo TherapeuticsSEC Form 47 May 2026Common Stock · traded 5 May 2026 · filed 7 May 2026
- exercised options over 77,905 shares of Avalo TherapeuticsSEC Form 47 May 2026Common Stock · traded 6 May 2026 · filed 7 May 2026
- exercised options over 28,650 shares of Avalo TherapeuticsSEC Form 47 May 2026Common Stock · traded 6 May 2026 · filed 7 May 2026
- ▼ sold on the open market 27,538 shares of Avalo TherapeuticsSEC Form 47 May 2026Common Stock · traded 6 May 2026 · filed 7 May 2026
- ▼ sold on the open market 5,000 shares of Avalo TherapeuticsSEC Form 47 May 2026Common Stock · traded 6 May 2026 · filed 7 May 2026
- ▼ sold on the open market 44,944 shares of Avalo TherapeuticsSEC Form 47 May 2026Common Stock · traded 6 May 2026 · filed 7 May 2026
- ▼ sold on the open market 19,015 shares of Avalo TherapeuticsSEC Form 47 May 2026Common Stock · traded 6 May 2026 · filed 7 May 2026
- exercised options over 3,970 shares of Avalo TherapeuticsSEC Form 48 April 2026Common Stock · traded 6 April 2026 · filed 8 April 2026
- ▼ sold on the open market 3,970 shares of Avalo TherapeuticsSEC Form 48 April 2026Common Stock · traded 6 April 2026 · filed 8 April 2026
- exercised options over 3,970 shares of Avalo Therapeutics (a derivative holding)SEC Form 48 April 2026Stock Option (Right to Buy) · traded 6 April 2026 · filed 8 April 2026
- exercised options over 679 shares of Avalo TherapeuticsSEC Form 43 April 2026Common Stock · traded 1 April 2026 · filed 3 April 2026
- ▼ sold on the open market 679 shares of Avalo TherapeuticsSEC Form 43 April 2026Common Stock · traded 1 April 2026 · filed 3 April 2026
- exercised options over 679 shares of Avalo Therapeutics (a derivative holding)SEC Form 43 April 2026Stock Option (Right to Buy) · traded 1 April 2026 · filed 3 April 2026
- exercised options over 19,500 shares of Avalo TherapeuticsSEC Form 418 March 2026Common Stock · traded 16 March 2026 · filed 18 March 2026
- exercised options over 5,992 shares of Avalo TherapeuticsSEC Form 418 March 2026Common Stock · traded 16 March 2026 · filed 18 March 2026
- ▼ sold on the open market 25,492 shares of Avalo TherapeuticsSEC Form 418 March 2026Common Stock · traded 16 March 2026 · filed 18 March 2026
- exercised options over 19,500 shares of Avalo Therapeutics (a derivative holding)SEC Form 418 March 2026Stock Option (Right to Buy) · traded 16 March 2026 · filed 18 March 2026
- exercised options over 5,992 shares of Avalo Therapeutics (a derivative holding)SEC Form 418 March 2026Stock Option (Right to Buy) · traded 16 March 2026 · filed 18 March 2026
- exercised options over 19,500 shares of Avalo Therapeutics (a derivative holding)SEC Form 418 March 2026Stock Option (Right to Buy) · traded 16 March 2026 · filed 18 March 2026
- exercised options over 5,992 shares of Avalo Therapeutics (a derivative holding)SEC Form 418 March 2026Stock Option (Right to Buy) · traded 16 March 2026 · filed 18 March 2026
- exercised options over 19,500 shares of Avalo TherapeuticsSEC Form 418 March 2026Common Stock · traded 16 March 2026 · filed 18 March 2026
- exercised options over 5,992 shares of Avalo TherapeuticsSEC Form 418 March 2026Common Stock · traded 16 March 2026 · filed 18 March 2026
- ▼ sold on the open market 25,492 shares of Avalo TherapeuticsSEC Form 418 March 2026Common Stock · traded 16 March 2026 · filed 18 March 2026
- was granted 105,000 shares of Avalo Therapeutics (a derivative holding)SEC Form 42 March 2026Stock Option (Right to Buy) · traded 26 February 2026 · filed 2 March 2026
- was granted 105,000 shares of Avalo Therapeutics (a derivative holding)SEC Form 42 March 2026Stock Option (Right to Buy) · traded 26 February 2026 · filed 2 March 2026
- had shares withheld for tax on 1,013 shares of Avalo TherapeuticsSEC Form 412 December 2025Common Stock · traded 10 December 2025 · filed 12 December 2025
- was granted 79,456 shares of Cullinan Therapeutics (a derivative holding)SEC Form 48 August 2025Stock Option (Right to Buy) · traded 7 August 2025 · filed 8 August 2025
- was granted 155,000 shares of Avalo Therapeutics (a derivative holding)SEC Form 430 January 2025Stock Option (Right to Buy) · traded 28 January 2025 · filed 30 January 2025
- was granted 234,000 shares of Avalo Therapeutics (a derivative holding)SEC Form 416 July 2024Stock Option (Right to Buy) · traded 15 July 2024 · filed 16 July 2024
- returned to the issuer 42,500 shares of DICE Therapeutics (a derivative holding)SEC Form 49 August 2023Stock Option (right to buy) · traded 9 August 2023 · filed 9 August 2023
- was granted 42,500 shares of DICE Therapeutics (a derivative holding)SEC Form 41 April 2022Stock Option (right to buy) · traded 31 March 2022 · filed 1 April 2022
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.